First Anti-Aging Vaccine Patent Filed to Target Aging Cells
Immorta Bio, a Miami-based biotechnology company, announced the filing of an international patent application for a new drug named SenoVax. This is the first vaccine in the senolytic immunotherapy class designed to eliminate aging cells that accumulate with age and cause chronic diseases. Longevity.Technology reports this. Photo from open sources. The vaccine works differently from traditional senolytics that use chemical agents to destroy aging cells. SenoVax activates the immune system, stimulating it to specifically identify and destroy the damaged cells. Aging cells contribute to inflammatory processes, accelerate organ degradation, and create a favorable environment for cancer development. Their removal is considered one of the most promising approaches in the fight against aging. According to Immorta Bio's president and chief scientific officer Dr. Thomas Ichim, the new therapy allows simultaneously to affect aging processes and tumor development. By removing aging cells, scientists hope to slow or even partially reverse physiological aging. Preliminary studies have shown a doubling of lifespan in animals. However, these results are limited to laboratory experiments and require further study. The company plans to begin clinical trials of the vaccine against lung cancer, and then expand the scope of research to age-related pathologies and the aging process itself. If early trials confirm the effectiveness of the vaccine, Immorta Bio intends to develop therapy for treating frailty, organ failure, and other late-life diseases.
In This Article:
- SenoVax Activates the Immune System to Target Damaged Cells
- Aging Cells Fuel Inflammation, Accelerate Organ Decline and Boost Cancer Risk
- Dr. Thomas Ichim Says the Therapy Targets Both Aging and Tumors
- Preclinical Results Show Lifespan Doubling in Animals; More Work Needed
- Clinical Plans: Lung Cancer Vaccine First, Then Broaden to Aging-Related Conditions
- If Early Trials Prove Effective, Immorta Bio Aims to Tackle Frailty, Organ Failure and Other Late-Life Diseases
SenoVax Activates the Immune System to Target Damaged Cells
The vaccine acts differently from traditional senolytics that use chemical substances to destroy aging cells. SenoVax activates the immune system, stimulating it to selectively identify and destroy the damaged cells.
Aging Cells Fuel Inflammation, Accelerate Organ Decline and Boost Cancer Risk
Aging cells contribute to inflammatory processes, accelerate organ degradation, and create a favorable environment for the development of cancer. Their removal is considered one of the most promising approaches in the fight against aging.
Dr. Thomas Ichim Says the Therapy Targets Both Aging and Tumors
According to Immorta Bio’s president and chief scientific officer Dr. Thomas Ichim, the new therapy allows simultaneously to affect aging processes and the development of tumors.
Preclinical Results Show Lifespan Doubling in Animals; More Work Needed
Preliminary studies have shown a twofold increase in animal lifespan. However, these results are limited to laboratory experiments and require further study.
Clinical Plans: Lung Cancer Vaccine First, Then Broaden to Aging-Related Conditions
The company plans to start clinical trials of the lung cancer vaccine, and then expand the scope of research to age-related pathologies and the aging process itself.
If Early Trials Prove Effective, Immorta Bio Aims to Tackle Frailty, Organ Failure and Other Late-Life Diseases
If early trials confirm the vaccine’s effectiveness, Immorta Bio intends to develop the therapy to treat frailty, organ failure, and other late-age diseases.
